Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study

An Outtier(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Olivier Dewit, Ganel Schops(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Cathérine Reenaers(Centre Hospitalier Universitaire de Liège), João Sabino(KU Leuven), Édouard Louis(Centre Hospitalier Universitaire de Liège), Matthias Lenfant(KU Leuven), Gert De Hertogh(KU Leuven), Emilie Pontus(Cliniques Universitaires Saint-Luc), Séverine Vermeire(KU Leuven)
Clinical Gastroenterology and Hepatology
May 14, 2024
10.1016/j.cgh.2024.04.030
Cited by 16

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k